<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Depth-of-Response–Adapted Duration for Anti–PD-1 in Advanced Melanoma - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-31</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-31</p>
                <p><strong>Name:</strong> Depth-of-Response–Adapted Duration for Anti–PD-1 in Advanced Melanoma</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of the optimal duration of anti-PD-1 immunotherapy for melanoma, and whether it differs by depth of response, based on the following results.</p>
                <p><strong>Description:</strong> Optimal anti–PD-1 duration depends on depth of response. Patients who achieve radiographic complete response (CR) can discontinue safely after a minimum effective exposure (≈6–12 months), whereas non-CR responders (PR/SD) require either longer exposure (≈24 months) or biomarker confirmation of minimal residual disease (e.g., PET complete metabolic response, biopsy negativity, ctDNA clearance) to achieve comparable off-therapy durability. This response-adapted framework reduces overtreatment while preserving disease control.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> openai/gpt-5</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Law 0</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Law 1</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>In PET-Stop (EA6192), PR patients who are PET-negative/biopsy-negative at 1 year and stop will have 24-month EFS ≥85%, similar to PR patients in KEYNOTE-006 who completed 2 years before stopping (≈82% PFS at 24 months).</li>
                <li>In DANTE, PR/SD patients randomized to continue after 12 months will outperform non-biomarker-selected early-stoppers, but PET/biopsy-selected early-stoppers will be non-inferior.</li>
                <li>Adding ctDNA negativity to PET CMR in PR will reduce 24-month relapse rates below 10% among early-stoppers.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>Safe Stop (NL7293) PR cohort early discontinuation after ~1 year will yield 2-year ongoing-response rate ≥80% if most are PET CMR, but <60% if PET selection is not applied.</li>
                <li>Localized ablation of oligometastatic PET-positive foci followed by early stop in PR will match 2-year PFS of systemic continuation in selected patients.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If biomarker-selected PR early-stoppers have ≥10% absolute lower 24-month PFS than continuers in randomized settings, the bifurcated rule would be invalidated.</li>
                <li>If CR patients treated <6 months show equivalent 24-month DFS to ≥6 months, the minimum effective exposure principle would be refuted.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Applicability to mucosal melanoma remains unclear; Dai 2023 PMME/NEMM cohort lacks discontinuation data. <a href="../results/extraction-result-75.html#e75.0" class="evidence-link">[e75.0]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>